The Role of the Surgeon in the Germline Testing of the Newly Diagnosed Breast Cancer Patient
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. The Prevalence of Germline Mutations in Breast Cancer Patients
3.2. The Benefits of Testing—How Does Genetic Testing Alter Clinical Decision-Making?
3.2.1. Local Therapy Decisions
3.2.2. The Risk of Contralateral Breast Cancer
3.2.3. The Impact on Systemic Therapy
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Clark, N.M.; Roberts, E.A.; Fedorenko, C.; Sun, Q.; Dubard-Gault, M.; Handford, C.; Yung, R.; Cheng, H.H.; Sham, J.G.; Norquist, B.M.; et al. Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers. Ann. Surg. Oncol. 2022, 30, 1312–1326. [Google Scholar] [CrossRef]
- Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 3.2023. Available online: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf (accessed on 26 February 2023).
- O’Leary, E.; Iacoboni, D.; Holle, J.; Michalski, S.T.; Esplin, E.D.; Yang, S.; Ouyang, K. Expanded Gene Panel Use for Women with Breast Cancer: Identification and Interven-tion Beyond Breast Cancer Risk. Ann. Surg. Oncol. 2017, 24, 3060–3066. [Google Scholar] [CrossRef] [PubMed]
- Tung, N.; Lin, N.U.; Kidd, J.; Allen, B.A.; Singh, N.; Wenstrup, R.J.; Hartman, A.-R.; Winer, E.P.; Garber, J.E. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients with Breast Cancer. J. Clin. Oncol. 2016, 34, 1460–1468. [Google Scholar] [CrossRef]
- Buys, S.S.; Sandbach, J.F.; Gammon, A.; Patel, M.; Kidd, J.; Brown, K.L.; Sharma, L.; Saam, J.; Lancaster, J.; Daly, M.B. A Study of Over 35,000 Women with Breast Cancer Tested with A 25-Gene Panel of Hereditary Cancer Genes. Cancer 2017, 123, 1721–1730. [Google Scholar] [CrossRef] [PubMed]
- Beitsch, P.D.; Whitworth, P.W.; Hughes, K.; Patel, R.; Rosen, B.; Compagnoni, G.; Baron, P.; Simmons, R.; Smith, L.A.; Grady, I.; et al. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? J. Clin. Oncol. 2019, 37, 453–460. [Google Scholar] [CrossRef]
- Hu, C.; Hart, S.N.; Gnanaolivu, R.; Huang, H.; Lee, K.Y.; Na, J.; Gao, C.; Lilyquist, J.; Yadav, S.; Boddicker, N.J.; et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N. Engl. J. Med. 2021, 384, 440–451. [Google Scholar] [CrossRef] [PubMed]
- Kurian, A.W.; Ward, K.C.; Howlader, N.; Deapen, D.; Hamilton, A.S.; Mariotto, A.; Miller, D.; Penberthy, L.S.; Katz, S.J. Genetic Testing and Results in a Population-Based Co-hort of Breast Cancer Patients and Ovarian Cancer Patients. J. Clin. Oncol. 2019, 37, 1305–1315. [Google Scholar] [CrossRef]
- Tung, N.; Batteli, C.; Allen, B.; Kaldate, R.; Bhatnagar, S.; Bowles, K.; Timms, K.; Garber, J.E.; Herold, C.; Ellisen, L.; et al. Frequency of Mutations in Individuals with Breast Cancer Referred for BRCA1 And BRCA2 Testing Using Next-Generation Sequencing with A 25-Gene Panel. Cancer 2015, 121, 25–33. [Google Scholar] [CrossRef]
- Pritzlaff, M.; Summerour, P.; McFarland, R.; Li, S.; Reineke, P.; Dolinsky, J.S.; Goldgar, D.E.; Shimelis, H.; Couch, F.J.; Chao, E.C.; et al. Male Breast Cancer in A Multi-Gene Panel Testing Cohort: In-Sights and Unexpected Results. Breast Cancer Res. Treat. 2017, 161, 575–586. [Google Scholar] [CrossRef]
- Rolfes, M.; Borde, J.; Möllenhoff, K.; Kayali, M.; Ernst, C.; Gehrig, A.; Sutter, C.; Ramser, J.; Niederacher, D.; Horváth, J.; et al. Prevalence of Cancer Predisposition Germline Variants in Male Breast Cancer Patients: Results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancers 2022, 14, 3292. [Google Scholar] [CrossRef]
- Yang, S.; Axilbund, J.E.; O’Leary, E.; Michalski, S.T.; Evans, R.; Lincoln, S.E.; Esplin, E.D.; Nussbaum, R.L. Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark. Ann. Surg. Oncol. 2018, 25, 2925–2931. [Google Scholar] [CrossRef]
- Consensus Guideline on Genetic Testing for Hereditary Breast Cancer. Version 2019. Available online: https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Genetic-Testing-for-Hereditary-Breast-Cancer.pdf (accessed on 25 February 2023).
- Yadav, S.; Hu, C.; Hart, S.N.; Boddicker, N.; Polley, E.C.; Na, J.; Gnanaolivu, R.; Lee, K.Y.; Lindstrom, T.; Armasu, S.; et al. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women with Breast Cancer. J. Clin. Oncol. 2020, 38, 1409–1418. [Google Scholar] [CrossRef]
- Valachis, A.; Nearchou, A.D.; Lind, P. Surgical management of breast cancer in BRCA-mutation carriers: A systematic review and meta-analysis. Breast Cancer Res. Treat. 2014, 144, 443–455. [Google Scholar] [CrossRef]
- Co, M.; Liu, T.; Leung, J.; Li, C.H.; Tse, T.; Wong, M.; Kwong, A. Breast Conserving Surgery for BRCA Mutation Carriers-A System-atic Review. Clin. Breast Cancer 2020, 20, e244–e250. [Google Scholar] [CrossRef] [PubMed]
- Tung, N.M.; Boughey, J.C.; Pierce, L.J.; Robson, M.E.; Bedrosian, I.; Dietz, J.R.; Dragun, A.; Gelpi, J.B.; Hofstatter, E.W.; Isaacs, C.J.; et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J. Clin. Oncol. 2020, 38, 2080–2106. [Google Scholar] [CrossRef]
- Mai, P.L.; Best, A.F.; Peters, J.A.; DeCastro, R.M.; Khincha, P.P.; Loud, J.T.; Bremer, R.C.; Rosenberg, P.S.; Savage, S.A. Risks of First and Subsequent Cancers among TP53 Mutation Car-Riers in The National Cancer Institute Li-Fraumeni Syndrome Cohort. Cancer 2016, 122, 3673–3681. [Google Scholar] [CrossRef]
- Guo, Y.; Wan, Q.; Ouyang, T.; Li, J.; Wang, T.; Fan, Z.; Xie, Y. Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients. Breast 2022, 65, 55–60. [Google Scholar] [CrossRef] [PubMed]
- Heymann, S.; Delaloge, S.; Rahal, A.; Caron, O.; Frebourg, T.; Barreau, L.; Pachet, C.; Mathieu, M.-C.; Marsiglia, H.; Bourgier, C. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat. Oncol. 2010, 5, 104. [Google Scholar] [CrossRef]
- Gondim, G.R.M.; Formiga, M.N.C.; Castro, D.G.; Silva, M.L.G.; Chen, M.; Fogaroli, R.; Ramos, H.; Coelho, T.M.; Pellizzon, A.C.A.; Da Costa, A.A.B.A. Adjuvant radiation therapy in patients with breast cancer and Li-Fraumeni syndrome: Oncologic results and incidence of second neoplasms. J. Clin. Oncol. 2018, 36, e12589. [Google Scholar] [CrossRef]
- Le, A.N.; Harton, J.; Desai, H.; Powers, J.; Zelley, K.; Bradbury, A.R.; Nathanson, K.L.; Shah, P.D.; Doucette, A.; Freedman, G.M.; et al. Frequency of Radiation-Induced Malignancies Post-Adjuvant Radiothera-Py for Breast Cancer in Patients with Li-Fraumeni Syndrome. Breast Cancer Res. Treat. 2020, 181, 181–188. [Google Scholar] [CrossRef] [PubMed]
- Bergstrom, C.; Pence, C.; Berg, J.; Partain, N.; Sadeghi, N.; Mauer, C.; Pirzadeh-Miller, S.; Gao, A.; Li, H.; Unni, N.; et al. Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations. Ann. Surg. Oncol. 2020, 28, 3383–3393. [Google Scholar] [CrossRef] [PubMed]
- Meyer, A.; Dörk, T.; Sohn, C.; Karstens, J.H.; Bremer, M. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy. Radiother. Oncol. 2007, 82, 349–353. [Google Scholar] [CrossRef] [PubMed]
- Chapman, B.V.; Liu, D.; Shen, Y.; Olamigoke, O.O.; Lakomy, D.S.; Barrera, A.M.G.; Stecklein, S.R.; Sawakuchi, G.O.; Bright, S.J.; Bedrosian, I.; et al. Breast Radiation Therapy–Related Treatment Outcomes in Patients with or Without Germline Mutations on Multigene Panel Testing. Int. J. Radiat. Oncol. 2021, 112, 437–444. [Google Scholar] [CrossRef]
- McDuff, S.G.R.; Bellon, J.R.; Shannon, K.M.; Gadd, M.A.; Dunn, S.; Rosenstein, B.S.; Ho, A.Y. ATM Variants in Breast Cancer: Implica-tions for Breast Radiation Therapy Treatment Recommendations. Int. J. Radiat. Oncol. Biol. Phys. 2021, 110, 1373–1382. [Google Scholar] [CrossRef] [PubMed]
- Robson, M. Management of Women with Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2. J. Clin. Oncol. 2021, 39, 2528–2534. [Google Scholar] [CrossRef] [PubMed]
- Yadav, S.; Boddicker, N.J.; Na, J.; Polley, E.C.; Hu, C.; Hart, S.N.; Gnanaolivu, R.D.; Larson, N.; Holtegaard, S.; Huang, H.; et al. Contralateral Breast Cancer Risk among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J. Clin. Oncol. 2023, 41, 1703–1713. [Google Scholar] [CrossRef]
- Mellemkjær, L.; The WECARE Study Collaborative Group; Dahl, C.; Olsen, J.H.; Bertelsen, L.; Guldberg, P.; Christensen, J.; Børresen-Dale, A.-L.; Stovall, M.; Langholz, B.; et al. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study. Br. J. Cancer 2008, 98, 728–733. [Google Scholar] [CrossRef]
- Graeser, M.K.; Engel, C.; Rhiem, K.; Gadzicki, D.; Bick, U.; Kast, K.; Froster, U.G.; Schlehe, B.; Bechtold, A.; Arnold, N.; et al. Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. J. Clin. Oncol. 2009, 27, 5887–5892. [Google Scholar] [CrossRef]
- Hyder, Z.; Harkness, E.F.; Woodward, E.R.; Bowers, N.L.; Pereira, M.; Wallace, A.J.; Howell, S.J.; Howell, A.; Lalloo, F.; Newman, W.G.; et al. Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer. Cancers 2020, 12, 378. [Google Scholar] [CrossRef]
- Teoh, V.; Tasoulis, M.K.; Gui, G. Contralateral Prophylactic Mastectomy in Women with Unilateral Breast Cancer Who Are Ge-netic Carriers, have a Strong Family History or Are just Young at Presentation. Cancers 2020, 12, 140. [Google Scholar] [CrossRef]
- van Sprundel, T.C.; Schmidt, M.K.; Rookus, M.A.; Brohet, R.; van Asperen, C.J.; Rutgers, E.J.; Van’t Veer, L.J.; Tollenaar, R.A. Risk Reduction of Contralateral Breast Cancer and Survival after Contralateral Prophylactic Mastectomy in BRCA1 or BRCA2 Mutation Carriers. Br. J. Cancer. 2005, 93, 287–292. [Google Scholar] [CrossRef] [PubMed]
- E Carbine, N.; Lostumbo, L.; Wallace, J.; Ko, H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst. Rev. 2018, 2019, CD002748. [Google Scholar] [CrossRef]
- Kurian, A.W.; Ward, K.C.; Abrahamse, P.; Hamilton, A.S.; Deapen, D.; Morrow, M.; Jagsi, R.; Katz, S.J. Association of Germline Genetic Testing Results with Locoregional and Systemic Therapy in Patients With Breast Cancer. JAMA Oncol. 2020, 6, e196400. [Google Scholar] [CrossRef] [PubMed]
- Chiba, A.; Hoskin, T.L.; Hallberg, E.J.; Cogswell, J.A.; Heins, C.N.; Couch, F.J.; Boughey, J.C. Impact that Timing of Genetic Mutation Diagnosis Has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer. Ann. Surg. Oncol. 2016, 23, 3232–3238. [Google Scholar] [CrossRef]
- Cortesi, L.; Rugo, H.S.; Jackisch, C. An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target. Oncol. 2021, 16, 255–282. [Google Scholar] [CrossRef]
- Robson, M.; Im, S.A.; Senkus, E.; Xu, B.; Domchek, S.M.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Armstrong, A.; et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med. 2017, 377, 523–533. [Google Scholar] [CrossRef]
- Litton, J.K.; Rugo, H.S.; Ettl, J.; Hurvitz, S.A.; Gonçalves, A.; Lee, K.-H.; Fehrenbacher, L.; Yerushalmi, R.; Mina, L.A.; Martin, M.; et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N. Engl. J. Med. 2018, 379, 753–763. [Google Scholar] [CrossRef] [PubMed]
- FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer (accessed on 10 February 2023).
- rtmański, S.; Metcalfe, K.; TrempaŁa, J.; Głowacka, M.D.; Lubiński, J.; Narod, S.A.; Gronwald, J. Identification of Patients at High Risk of Psychological Distress After BRCA1 Genetic Testing. Genet. Test. Mol. Biomarkers 2009, 13, 325–330. [Google Scholar] [CrossRef]
- Makhnoon, S.; Bednar, E.M.; Krause, K.J.; Peterson, S.K.; Lopez-Olivo, M.A. Clinical Management among Individuals with Variant of Uncertain Significance in Hereditary Cancer: A Systematic Review and Meta-Analysis. Clin. Genet. 2021, 100, 119–131. [Google Scholar] [CrossRef]
- Plichta, J.K.; Sebastian, M.L.; Smith, L.A.; Menendez, C.S.; Johnson, A.T.; Bays, S.M.; Euhus, D.M.; Clifford, E.J.; Jalali, M.; Kurtzman, S.H.; et al. Germline Genetic Testing: What the Breast Surgeon Needs to Know. Ann. Surg. Oncol. 2019, 26, 2184–2190. [Google Scholar] [CrossRef]
- Kiechle, M.; Engel, C.; Berling, A.; Hebestreit, K.; Bischoff, S.; Dukatz, R.; Gerber, W.D.; Siniatchkin, M.; Pfeifer, K.; Grill, S.; et al. Lifestyle Intervention in BRCA1/2 Mutation Carriers: Study Protocol for A Prospective, Randomized, Controlled Clinical Feasibility Trial (LIBRE-1 Study). Pilot. Feasibil. Study 2016, 2, 74. [Google Scholar] [CrossRef] [PubMed]
- Stenehjem, D.D.; Au, T.; Sainski, A.M.; Bauer, H.; Brown, K.; Lancaster, J.; Stevens, V.; Brixner, D.I. Impact of a genetic counseling requirement prior to genetic testing. BMC Health Serv. Res. 2018, 18, 1–11. [Google Scholar] [CrossRef]
- National Society of Genetic Counselors Executive Summary. April 2021. Available online: https://www.nsgc.org/Portals/0/Executive%20Summary%202021%20FINAL%2005-03-21.pdf (accessed on 21 February 2023).
- Bracke, X.; Roberts, J.; McVeigh, T.P. A Systematic Review and Meta-Analysis of Telephone Vs In-Person Genetic Counseling in BRCA1/BRCA2 Genetic Testing. J. Genet. Couns. 2021, 30, 563–573. [Google Scholar] [CrossRef] [PubMed]
- Zierhut, H.A.; MacFarlane, I.M.; Ahmed, Z.; Davies, J. Genetic Counselors’ Experiences and Interest in Telegenetics and Remote Counseling. J. Genet. Couns. 2018, 27, 329–338. [Google Scholar] [CrossRef] [PubMed]
- Cacioppo, C.N.; Egleston, B.L.; Fetzer, D.; Sands, C.B.; Raza, S.A.; Malleda, N.R.; Wood, E.M.; Rittenburg, I.; Childs, J.; Cho, D.; et al. Randomized study of remote telehealth genetic services versus usual care in oncology practices without genetic counselors. Cancer Med. 2021, 10, 4532–4541. [Google Scholar] [CrossRef]
- Brown, E.G.; Watts, I.; Beales, E.R.; Maudhoo, A.; Hayward, J.; Sheridan, E.; Rafi, I. Videoconferencing to deliver genetics services: A systematic review of telegenetics in light of the COVID-19 pandemic. Anesthesia Analg. 2021, 23, 1438–1449. [Google Scholar] [CrossRef]
- Ochoa, D.; Jean-Louis, C.; Stephenson, K.; Woods, M.; Kelsey, J.; Henry-Tillman, R. What happens after referral? Completion rates of genetic counseling evaluations in breast cancer patients. J. Natl. Med Assoc. 2022, 114, 90–93. [Google Scholar] [CrossRef]
- Culver, J.O.; Freiberg, Y.; Ricker, C.; Comeaux, J.G.; Chang, E.Y.; Banerjee, V.; Sturgeon, D.; Solomon, I.; Kagey, J.; Dobre, M.G.; et al. Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients. Ann. Surg. Oncol. 2022, 30, 1017–1025. [Google Scholar] [CrossRef]
- Rana, H.Q.; Kipnis, L.; Hehir, K.; Cronin, A.; Jaung, T.; Stokes, S.M.; Fekrmandi, F.; Vatnick, D.; Matulonis, U.A.; Garber, J.E.; et al. Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. Gynecol. Oncol. 2020, 160, 457–463. [Google Scholar] [CrossRef]
- Optimal Resources for Breast Care 2024 Standards. Version February 2023. Available online: https://accreditation.facs.org/accreditationdocuments/NAPBC/Standards/Optimal_Resources_for_Breast_Care_2024.pdf (accessed on 26 February 2023).
- Optimal Resources for Cancer Care 2020 Standards. Version April 2023. Available online: https://www.facs.org/media/whmfnppx/2020_coc_standards.pdf (accessed on 26 February 2023).
- Robson, M.E.; Bradbury, A.R.; Arun, B.; Domchek, S.M.; Ford, J.M.; Hampel, H.L.; Lipkin, S.M.; Syngal, S.; Wollins, D.S.; Lindor, N.M. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J. Clin. Oncol. 2015, 33, 3660–3667. [Google Scholar] [CrossRef]
- Ain, Q.; Richardson, C.; Mutebi, M.; George, A.; Kemp, Z.; Rusby, J.E. Does Mainstream BRCA Testing Affect Surgical Decision-Making in Newly Diagnosed Breast Cancer Patients? Breast 2023, 67, 30–35. [Google Scholar] [CrossRef] [PubMed]
- Beitsch, P.D.; Whitworth, P.W. Can Breast Surgeons Provide Breast Cancer Genetic Testing? An American Society of Breast Sur-geons survey. Ann. Surg. Oncol. 2014, 21, 4104–4108. [Google Scholar] [CrossRef] [PubMed]
- Genetics and Genomics. Available online: https://education.asco.org/coursecollection/genetics-and-genomics (accessed on 26 February 2023).
- Bringing Genetic Testing into Your Clinic. Available online: https://www.breastsurgeons.org/meeting/2023/pre/genetic (accessed on 26 February 2023).
- Intensive Course in Genetic Cancer Risk Assessment 2023. Available online: https://www.cityofhope.org/academics/health-professional-education/cancer-genomics-education-program/intensive-course-in-cancer-risk-assessment-overview (accessed on 26 February 2023).
Individual with blood relative with PV/LPV in cancer susceptibility gene |
Individuals who previously tested negative by limited testing panel |
Breast cancer diagnosis ≤ age 50 |
Male breast cancer regardless of age |
Triple negative histology regardless of age |
Ashkenazi Jewish ancestry regardless of age |
Lobular histology with personal or family history of diffuse gastric cancer |
Multiple breast primaries |
High risk cancers who may be considered candidates for molecular targeted agents |
Metastatic breast cancers |
Personal history of breast cancer with close family members with breast cancer ≤ age 50, ovarian cancer, prostate cancer, male breast cancer, pancreatic cancer |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Schick, S.; Manghelli, J.; Ludwig, K.K. The Role of the Surgeon in the Germline Testing of the Newly Diagnosed Breast Cancer Patient. Curr. Oncol. 2023, 30, 4677-4687. https://doi.org/10.3390/curroncol30050353
Schick S, Manghelli J, Ludwig KK. The Role of the Surgeon in the Germline Testing of the Newly Diagnosed Breast Cancer Patient. Current Oncology. 2023; 30(5):4677-4687. https://doi.org/10.3390/curroncol30050353
Chicago/Turabian StyleSchick, Stephanie, Joshua Manghelli, and Kandice K. Ludwig. 2023. "The Role of the Surgeon in the Germline Testing of the Newly Diagnosed Breast Cancer Patient" Current Oncology 30, no. 5: 4677-4687. https://doi.org/10.3390/curroncol30050353